Company

Metacrine, Inc.

Metacrine is a San Diego biopharmaceutical company developing therapies for liver and gastrointestinal diseases.

About

Founded in 2014 by Ronald Evans and headquartered in San Diego, California, Metacrine, Inc. develops treatments for liver and gastrointestinal disorders, with a focus on its FXR program for NASH. The company raised USD 85.02 mn in its IPO in September 2020, selling 6.54 million shares at USD 13 per share. Its EBITDA for 2021 was -USD 60.11 mn. The listed stage is Series C.

5Funding rounds

12Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in